NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014

NeuroVive’s research wins award at international research symposium

Second Quarter (1 Apr. 2014 – 30 Jun. 2014)

  • Net revenues were SEK 0 (5,335,000) and other operating income was SEK 1,128,000 (704,000).
  • Loss before tax was SEK -13,690,000 (-1,467,000).
  • Earnings per share* were SEK -0.69 (-0.15).
  • Diluted earnings per share** were SEK -0.69 (-0.15).

Six months (1 Jan. 2014 – 30 Jun. 2014)

  • Net revenues were SEK 0 (5,335,000) and other operating income was SEK 1,171,000 (863,000).
  • Loss before tax was SEK -23,567,000 (-6,206,000).
  • Earnings per share* were SEK -0.93 (-0.39).
  • Diluted earnings per share** were SEK-0.93 (-0.39).

* Profit/loss for the period divided by the average number of shares before dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

Business highlights in the second quarter of 2014

  • NeuroVive signs new agreement with Hospices Civils de Lyon. NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive’s cardiovascular business area and creates the right conditions for the company to retain its leading position in mitochondrial medicine. The new collaboration agreement, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, providing NeuroVive with access to medical technology and patient groups for the evaluation of its drug candidates.
     
  • NeuroVive’s research into energy regulation wins award at the international research symposium Mitochondrial Medicine 2014 held in Pittsburgh, USA, on 4-7 June. NeuroVive presented research containing underlying scientific data on its energy regulators (NVP015). The paper was selected for oral presentation and won second prize.

Read the interim report attached below

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8:30 CEST on August 20, 2014.

NeuroVive Pharmaceutical AB (publ) is a leading mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US, under the ticker symbol NEVPFUS

Tags:

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). www.neurovive.com

Subscribe

Documents & Links